[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615916":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Second Affiliated Hospital of Nanchang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Probiotic group","ACTIVE_COMPARATOR","Oral administration of the investigational probiotic powder MR-61. The primary component is Bifidobacterium. Dosage: one sachet, 2-3 times daily, for 3 months.",[13],"Biological: Investigational Bifidobacterium Preparation MR-61",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Oral administration of a matched placebo powder. Dosage: one sachet, 2-3 times daily, for 3 months.",[19],"Other: Placebo for MR-61",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","Investigational Bifidobacterium Preparation MR-61",[9],null,{"type":6,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Placebo for MR-61",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Yifeng Yu, Ph.D","CONTACT","13979180258","171018170@qq.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Yifeng Yu","RECRUITING","Nanchang","Jiangxi","330008","China","CN",{"type":45,"coordinates":46},"Point",[47,48],115.85306,28.68396,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":25,"email":34},"yifeng Yu, Ph.D","+8613979180258",{"type":55,"investigatorFullName":37,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Associate Chief Physician, Ph.D.","100615916","phase-2-clinical-efficacy-and-mechanism-exploration-of-mr-61-in-delaying-the-progression-of-myopia-100615916",false,"NCT07298824","Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia","Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n1. Myopia is defined as spherical equivalent (SE) ≤ -0.5D.\n2. Aged between 3 and 18 years, with no restriction on gender.\n3. Cylinder power ≤ 1.50D; anisometropia of SE between both eyes ≤ 1.50D.\n4. The subject has sufficient compliance with the study follow-up; the subject or their guardian has the intention to receive treatment and has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of other concomitant ocular diseases;\n2. Abnormal findings on clinical slit-lamp examination;\n3. Existence of amblyopia, manifest strabismus, esotropia, or other congenital ocular diseases;\n4. Individuals with abnormal intraocular pressure or abnormal axial length of the eye;\n5. Either or both parents having a spherical equivalent (SE) ≤ -6.00D;\n6. Other conditions inconsistent with this study.","ALL","3 Years","18 Years",{"count":68,"type":69},164,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).",[75],"Myopia Progressing",[77],"Myopia,Probiotics,Gut microbiota","2025-12-20",{"date":80,"type":81},"2025-12-23","ACTUAL",{"date":83,"type":81},"2025-10-01",{"date":85,"type":69},"2027-07-01",{"name":5,"class":6},1]